Education
About Us
Working with TipRanks
Follow Us
PharmAla Biotech Holdings, Inc. (TSE:MDMA)
:MDMA
Total Valuation
PharmAla Biotech Holdings, Inc. has a market cap or net worth of C$11.98M. The enterprise value is C$10.18M.
Market CapC$11.98M
Enterprise ValueC$10.18M
Share Statistics
PharmAla Biotech Holdings, Inc. has 108,887,215 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding108,887,215
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
PharmAla Biotech Holdings, Inc.’s return on equity (ROE) is -0.88 and return on invested capital (ROIC) is -87.60%.
Return on Equity (ROE)-0.88
Return on Assets (ROA)-0.64
Return on Invested Capital (ROIC)-87.60%
Return on Capital Employed (ROCE)-0.88
Revenue Per Employee10.00T>
Profits Per Employee-10.00T>
Employee Count―
Asset Turnover0.18
Inventory Turnover3.92
Valuation Ratios
The current PE Ratio of PharmAla Biotech Holdings, Inc. is ―. PharmAla Biotech Holdings, Inc.’s PEG ratio is -0.05.
PE Ratio―
PS Ratio22.20
PB Ratio5.47
Price to Fair Value5.47
Price to FCF-12.84
Price to Operating Cash Flow-12.90
PEG Ratio-0.05
Income Statement
In the last 12 months, PharmAla Biotech Holdings, Inc. had revenue of 605.50K and earned -2.18M in profits. Earnings per share was -0.02.
Revenue605.50K
Gross Profit-845.17K
Operating Income-2.15M
Pretax Income-2.18M
Net Income-2.18M
EBITDA-2.07M
Earnings Per Share (EPS)-0.02
Cash Flow
In the last 12 months, operating cash flow was -921.03K and capital expenditures -10.38K, giving a free cash flow of -931.40K billion.
Operating Cash Flow-921.03K
Free Cash Flow-931.40K
Free Cash Flow per Share>-0.01
Dividends & Yields
PharmAla Biotech Holdings, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.25
52-Week Price Change-59.26%
50-Day Moving Average0.11
200-Day Moving Average0.12
Relative Strength Index (RSI)50.71
Average Volume (3m)208.17K
Important Dates
PharmAla Biotech Holdings, Inc. upcoming earnings date is Feb 2, 2026, After Close (Confirmed).
Last Earnings DateDec 24, 2025
Next Earnings DateFeb 2, 2026
Ex-Dividend Date―
Financial Position
PharmAla Biotech Holdings, Inc. as a current ratio of 1.71, with Debt / Equity ratio of 0.00%
Current Ratio1.71
Quick Ratio1.33
Debt to Market Cap0.00
Net Debt to EBITDA0.02
Interest Coverage Ratio0.00
Taxes
In the past 12 months, PharmAla Biotech Holdings, Inc. has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
PharmAla Biotech Holdings, Inc. EV to EBITDA ratio is -6.47, with an EV/FCF ratio of -12.81.
EV to Sales22.13
EV to EBITDA-6.47
EV to Free Cash Flow-12.81
EV to Operating Cash Flow-12.84
Balance Sheet
PharmAla Biotech Holdings, Inc. has C$857.05K in cash and marketable securities with C$0.00 in debt, giving a net cash position of C$857.05K billion.
Cash & Marketable SecuritiesC$857.05K
Total DebtC$0.00
Net CashC$857.05K
Net Cash Per Share<C$0.01
Tangible Book Value Per Share<C$0.01
Margins
Gross margin is -124.52%, with operating margin of -355.61%, and net profit margin of -359.25%.
Gross Margin-124.52%
Operating Margin-355.61%
Pretax Margin-359.25%
Net Profit Margin-359.25%
EBITDA Margin-342.17%
EBIT Margin-361.50%
Analyst Forecast
The average price target for PharmAla Biotech Holdings, Inc. is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast-72.51%
EPS Growth Forecast-170.13%